Peter Hirth - 04 Nov 2021 Form 3 Insider Report for IO Biotech, Inc. (IOBT)

Role
Director
Signature
/s/ Brian Burkavage, Attorney-in-Fact for Peter Hirth
Issuer symbol
IOBT
Transactions as of
04 Nov 2021
Net transactions value
$0
Form type
3
Filing time
04 Nov 2021, 21:32:49 UTC
Previous filing
17 Jun 2021
Next filing
31 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IOBT Warrants (Right to Buy) 04 Nov 2021 Common Stock 4,430 $13.97 Direct F1, F2
holding IOBT Warrants (Right to Buy) 04 Nov 2021 Common Stock 6,513 $15.36 Direct F2, F3
holding IOBT Warrants (Right to Buy) 04 Nov 2021 Common Stock 13,935 $12.64 Direct F2, F4
holding IOBT Warrants (Right to Buy) 04 Nov 2021 Common Stock 1,265 $19.62 Direct F2, F4
holding IOBT Warrants (Right to Buy) 04 Nov 2021 Common Stock 17,390 $12.64 Direct F2, F4
holding IOBT Warrants (Right to Buy) 04 Nov 2021 Common Stock 67,162 $12.64 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These Warrants vested in 25% annual increments on December 31 of each year following the November 23, 2016 grant date.
F2 Warrants expire in annual increments on the fifth anniversary of the vesting date.
F3 These Warrants vested in 25% annual increments on December 31 of each year following the February 21, 2017 grant date.
F4 These Warrants vest in 1/48 monthly increments after the May 27, 2021 vesting commencement date, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.
F5 These Warrants vest in 1/48 monthly increments after October 15, 2021 vesting commencement date, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney